Gabriel A Brooks

List of Publications by Year in Descending Order

53 papers	1,028 citations	14 h-index	31 g-index
62 ext. papers	1,313 ext. citations	4.8 avg, IF	4.54 L-index

#	Paper	IF	Citations
53	Revisiting Pharmacogenetic Testing Before Irinotecan-Why Not?. *JCO Oncology Practice*, **2022**, OP2100840	4.9	
52	Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment.. *Journal of Clinical Oncology*, **2022**, JCO2102342	2.2	2
51	Measuring Racial Inequities In The Quality Of Care Across Oncology Practices In The US.. *Health Affairs*, **2022**, 41, 598-606		0
50	Development of dynamic health care delivery heatmaps for end-of-life cancer care: a cohort study.. *BMJ Open*, **2022**, 12, e056328	3	0
49	Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes. *JAMA - Journal of the American Medical Association*, **2021**, 326, 1829-1839	27.4	10
48	How Do Claims-Based Measures of End-of-Life Care Compare to Family Ratings of Care Quality?. *Journal of the American Geriatrics Society*, **2021**, 69, 900-907	5.6	0
47	Fever-range hyperthermia promotes cGAS-STING pathway and synergizes DMXAA-induced antiviral immunity. *International Journal of Hyperthermia*, **2021**, 38, 30-37	3.7	2
46	Evaluation of Reliability and Correlations of Quality Measures in Cancer Care. *JAMA Network Open*, **2021**, 4, e212474	10.4	7
45	Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis. *Oncologist*, **2021**, 26, 1008-1016	5.7	2
44	End-of-life quality metrics among medicare decedents at minority-serving cancer centers: A retrospective study. *Cancer Medicine*, **2020**, 9, 1911-1921	4.8	14
43	Impact of neuroimaging in the pretreatment evaluation of early stage non-small cell lung cancer. *Heliyon*, **2020**, 6, e04319	3.6	2
42	Role of norms in variation in cancer centersSend-of-life quality: qualitative case study protocol. *BMC Palliative Care*, **2020**, 19, 136	3	1
41	Translation of Patient-Reported Outcomes in Oncology Clinical Trials to Everyday Practice. *Annals of Surgical Oncology*, **2020**, 27, 65-72	3.1	5
40	FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. *Cancer*, **2019**, 125, 2213-2221	6.4	6
39	Treatment delays during FOLFOX chemotherapy in patients with colorectal cancer: a multicenter retrospective analysis. *Journal of Gastrointestinal Oncology*, **2019**, 10, 841-846	2.8	3
38	Risk of treatment-related death in carriers of pathogenic DPYD polymorphisms treated with fluoropyrimidine chemotherapy: A systematic review and patient-level analysis.. *Journal of Clinical Oncology*, **2019**, 37, e15132-e15132	2.2	2
37	A Systematic Review of Clinical Decision Support Systems for Clinical Oncology Practice. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2019**, 17, 331-338	7.3	30

#	Reference		
36	Quality of end-of-life cancer care at minority-serving US cancer centers: A retrospective study of Medicare claims data.. *Journal of Clinical Oncology*, **2019**, 37, 6507-6507	2.2	0
35	Hospitalization Risk During Chemotherapy for Advanced Cancer: Development and Validation of Risk Stratification Models Using Real-World Data. *JCO Clinical Cancer Informatics*, **2019**, 3, 1-10	5.2	5
34	Classifying Stage IV Lung Cancer From Health Care Claims: A Comparison of Multiple Analytic Approaches. *JCO Clinical Cancer Informatics*, **2019**, 3, 1-19	5.2	3
33	Early Findings From the Oncology Care Model Evaluation. *Journal of Oncology Practice*, **2019**, 15, e888-e896	3.9	8
32	Comparison of treatment of early-stage breast cancer among NursesSHealth Study participants and other Medicare beneficiaries. *Breast Cancer Research and Treatment*, **2019**, 174, 759-767	4.4	4
31	Medicare Spending for Breast, Prostate, Lung, and Colorectal Cancer Patients in the Year of Diagnosis and Year of Death. *Health Services Research*, **2018**, 53, 2118-2132	3.4	9
30	Estimating Costs of Care Attributable to Cancer: Does the Choice of Comparison Group Matter?. *Health Services Research*, **2018**, 53 Suppl 1, 3227-3244	3.4	8
29	Classifying lung cancer stage from health care claims with a clinical algorithm or a machine-learning approach.. *Journal of Clinical Oncology*, **2018**, 36, 6589-6589	2.2	1
28	Unplanned delays among patients receiving FOLFOX chemotherapy for colorectal cancer.. *Journal of Clinical Oncology*, **2018**, 36, e15637-e15637	2.2	
27	Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non-Small Cell Lung Cancer. *JAMA Network Open*, **2018**, 1, e183023	10.4	3
26	Characteristics Associated with In-Hospital Death among Commercially Insured Decedents with Cancer. *Journal of Palliative Medicine*, **2017**, 20, 42-47	2.2	3
25	The Affordable Care Act and Cancer Care Delivery. *Cancer Journal (Sudbury, Mass)*, **2017**, 23, 163-167	2.2	20
24	Emergency Department Management of Patients With Febrile Neutropenia: Guideline Concordant or Overly Aggressive?. *Academic Emergency Medicine*, **2017**, 24, 83-91	3.4	21
23	Value-Based Medicine and Integration of Tumor Biology. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 833-840	7.1	3
22	An administrative stage inference algorithm for use in patients receiving chemotherapy for colorectal cancer.. *Journal of Clinical Oncology*, **2017**, 35, e18121-e18121	2.2	1
21	Classifying Lung Cancer Severity with Ensemble Machine Learning in Health Care Claims Data. *Proceedings of Machine Learning Research*, **2017**, 68, 25-38	0.4	14
20	An ED pilot intervention to facilitate outpatient acute care for cancer patients. *American Journal of Emergency Medicine*, **2016**, 34, 1934-1938	2.9	8
19	The relationship between primary tumor sidedness and prognosis in colorectal cancer.. *Journal of Clinical Oncology*, **2016**, 34, 3505-3505	2.2	37

18	Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA).. *Journal of Clinical Oncology*, **2016**, 34, 4-4	2.2	13
17	Characteristics associated with in-hospital death in commercially insured decedent.. *Journal of Clinical Oncology*, **2016**, 34, 35-35	2.2	
16	A pragmatic approach for measuring and monitoring hospitalizations in patients receiving chemotherapy for pancreatic cancer.. *Journal of Clinical Oncology*, **2016**, 34, 278-278	2.2	
15	Hospitalizations and deaths within 60 days of fluoropyrimidine chemotherapy initiation among Medicare patients with colorectal cancer.. *Journal of Clinical Oncology*, **2016**, 34, 3603-3603	2.2	
14	Intensity of Medical Interventions between Diagnosis and Death in Patients with Advanced Lung and Colorectal Cancer: A CanCORS Analysis. *Journal of Palliative Medicine*, **2016**, 19, 42-50	2.2	11
13	Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size: Positive Implications for Future Targeted Screening. *Pancreas*, **2016**, 45, 1062-6	2.6	19
12	Provider familiarity with specialty society guidelines for risk stratification and management of patients with febrile neutropenia. *American Journal of Emergency Medicine*, **2016**, 34, 1704-5	2.9	6
11	Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. *Oncologist*, **2016**, 21, 594-9	5.7	366
10	A Clinical Prediction Model to Assess Risk for Chemotherapy-Related Hospitalization in Patients Initiating Palliative Chemotherapy. *JAMA Oncology*, **2015**, 1, 441-7	13.4	31
9	Clinician perspectives on potentially avoidable hospitalizations in patients with cancer. *JAMA Oncology*, **2015**, 1, 109-110	13.4	19
8	How should we estimate costs of care attributable to cancer?. *Journal of Clinical Oncology*, **2015**, 33, 6503-6503	2.2	
7	National trends in pancreatic cancer outcomes and pattern of care among Medicare beneficiaries, 2000 through 2010. *Cancer*, **2014**, 120, 1050-8	6.4	10
6	Identification of potentially avoidable hospitalizations in patients with GI cancer. *Journal of Clinical Oncology*, **2014**, 32, 496-503	2.2	96
5	Tbx5 is required for avian and Mammalian epicardial formation and coronary vasculogenesis. *Circulation Research*, **2014**, 115, 834-44	15.7	23
4	Acute hospital care is the chief driver of regional spending variation in Medicare patients with advanced cancer. *Health Affairs*, **2014**, 33, 1793-800	7	85
3	Regional variation in spending and survival for older adults with advanced cancer. *Journal of the National Cancer Institute*, **2013**, 105, 634-42	9.7	72
2	Risk factors for the development of chemotherapy-related hospitalization (CRH) in patients treated with palliative intent: Results of a 9-year nested case control study.. *Journal of Clinical Oncology*, **2013**, 31, 3-3	2.2	
1	Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic. *Cancer Biology and Therapy*, **2006**, 5, 1098-102	4.6	23